
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4AE928AF30C9305AE92000154D3AA.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="sigtrans">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368246/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Signal Transduction and Targeted Therapy">
<meta name="citation_title" content="First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study">
<meta name="citation_author" content="Guoming Shi">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Xiaoyong Huang">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Liang Ma">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021 China">
<meta name="citation_author" content="Hui Li">
<meta name="citation_author_institution" content="Department of Oncology, The Affiliated Hospital of Jining Medical University, Jining, 272000 China">
<meta name="citation_author" content="Jianhong Zhong">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021 China">
<meta name="citation_author" content="Junye Wang">
<meta name="citation_author_institution" content="Department of Oncology, The Affiliated Hospital of Jining Medical University, Jining, 272000 China">
<meta name="citation_author" content="Qiang Gao">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Xiaojun Guo">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Shuangjian Qiu">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Huichuan Sun">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Yinghong Shi">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Xiaowu Huang">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Xiaoying Wang">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Yong Yi">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Xiaodong Zhu">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Cheng Huang">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Zhenbin Ding">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Yi Chen">
<meta name="citation_author_institution" content="Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Yifeng He">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Yinghao Shen">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Qiman Sun">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Jian Zhou">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_author" content="Jia Fan">
<meta name="citation_author_institution" content="Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="10">
<meta name="citation_firstpage" content="260">
<meta name="citation_doi" content="10.1038/s41392-025-02356-y">
<meta name="citation_pmid" content="40835595">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368246/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368246/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368246/pdf/41392_2025_Article_2356.pdf">
<meta name="description" content="Adding a PD-1/PD-L1 inhibitor to gemcitabine plus cisplatin (GemCis) has shown survival benefits in advanced biliary tract cancer (BTC). Dual inhibition of PD-1/PD-L1 and TIGIT may act synergistically, and further enhance antitumor effects. ZSAB-TOP ...">
<meta name="og:title" content="First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Adding a PD-1/PD-L1 inhibitor to gemcitabine plus cisplatin (GemCis) has shown survival benefits in advanced biliary tract cancer (BTC). Dual inhibition of PD-1/PD-L1 and TIGIT may act synergistically, and further enhance antitumor effects. ZSAB-TOP ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368246/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12368246">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41392-025-02356-y"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41392_2025_Article_2356.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12368246%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12368246/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12368246/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368246/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-sigtrans.jpg" alt="Signal Transduction and Targeted Therapy logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Signal Transduction and Targeted Therapy" title="Link to Signal Transduction and Targeted Therapy" shape="default" href="https://www.nature.com/sigtrans/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Signal Transduct Target Ther</button></div>. 2025 Aug 21;10:260. doi: <a href="https://doi.org/10.1038/s41392-025-02356-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41392-025-02356-y</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Signal%20Transduct%20Target%20Ther%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Signal%20Transduct%20Target%20Ther%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Signal%20Transduct%20Target%20Ther%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Signal%20Transduct%20Target%20Ther%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shi%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Guoming Shi</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Guoming Shi</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shi%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Guoming Shi</span></a>
</div>
</div>
<sup>1,</sup><sup>✉,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Xiaoyong Huang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Xiaoyong Huang</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoyong Huang</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Liang Ma</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Liang Ma</span></h3>
<div class="p">
<sup>2</sup>Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Liang Ma</span></a>
</div>
</div>
<sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Hui Li</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Hui Li</span></h3>
<div class="p">
<sup>3</sup>Department of Oncology, The Affiliated Hospital of Jining Medical University, Jining, 272000 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hui Li</span></a>
</div>
</div>
<sup>3,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhong%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Jianhong Zhong</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Jianhong Zhong</span></h3>
<div class="p">
<sup>2</sup>Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhong%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jianhong Zhong</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Junye Wang</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Junye Wang</span></h3>
<div class="p">
<sup>3</sup>Department of Oncology, The Affiliated Hospital of Jining Medical University, Jining, 272000 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Junye Wang</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Qiang Gao</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Qiang Gao</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qiang Gao</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guo%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Xiaojun Guo</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Xiaojun Guo</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guo%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaojun Guo</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qiu%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Shuangjian Qiu</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Shuangjian Qiu</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qiu%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shuangjian Qiu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Huichuan Sun</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Huichuan Sun</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Huichuan Sun</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shi%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Yinghong Shi</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Yinghong Shi</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shi%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yinghong Shi</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Xiaowu Huang</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Xiaowu Huang</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaowu Huang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Xiaoying Wang</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Xiaoying Wang</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoying Wang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yi%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Yong Yi</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Yong Yi</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yi%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yong Yi</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Xiaodong Zhu</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Xiaodong Zhu</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaodong Zhu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Cheng Huang</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Cheng Huang</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Cheng Huang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ding%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Zhenbin Ding</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Zhenbin Ding</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ding%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhenbin Ding</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Yi Chen</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Yi Chen</span></h3>
<div class="p">
<sup>4</sup>Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yi Chen</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Yifeng He</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Yifeng He</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yifeng He</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Yinghao Shen</span></a><div hidden="hidden" id="id20">
<h3><span class="name western">Yinghao Shen</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yinghao Shen</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Qiman Sun</span></a><div hidden="hidden" id="id21">
<h3><span class="name western">Qiman Sun</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qiman Sun</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id22"><span class="name western">Jian Zhou</span></a><div hidden="hidden" id="id22">
<h3><span class="name western">Jian Zhou</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jian Zhou</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fan%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id23"><span class="name western">Jia Fan</span></a><div hidden="hidden" id="id23">
<h3><span class="name western">Jia Fan</span></h3>
<div class="p">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fan%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jia Fan</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div id="Aff2">
<sup>2</sup>Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021 China </div>
<div id="Aff3">
<sup>3</sup>Department of Oncology, The Affiliated Hospital of Jining Medical University, Jining, 272000 China </div>
<div id="Aff4">
<sup>4</sup>Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032 China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 10; Revised 2025 Jun 15; Accepted 2025 Jul 14; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12368246  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40835595/" class="usa-link">40835595</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Adding a PD-1/PD-L1 inhibitor to gemcitabine plus cisplatin (GemCis) has shown survival benefits in advanced biliary tract cancer (BTC). Dual inhibition of PD-1/PD-L1 and TIGIT may act synergistically, and further enhance antitumor effects. ZSAB-TOP was a single-arm, multicenter, phase 2 study (<a href="https://clinicaltrials.gov/ct2/show/NCT05023109" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05023109</a>) evaluating efficacy and safety of first-line tislelizumab (a PD-1 inhibitor) plus ociperlimab (a TIGIT inhibitor) and GemCis in advanced BTC. Eligible patients received tislelizumab (200 mg) and ociperlimab (900 mg) on day 1 until unacceptable toxicity or disease progression, in combination with cisplatin (25 mg/m²) and gemcitabine (1000 mg/m²) on days 1 and 8 of a 21-day cycle for a maximum eight cycles. The primary endpoint was confirmed objective response rate (ORR) evaluated by the investigator, which was compared with a historical ORR of 25% with GemCis, with a statistical superiority setting at p ≤ 0.05. From March 8, 2022, to January 18, 2023, 45 patients were enrolled. Among the 41 patients in the efficacy analysis set, the confirmed ORR was 51.2% (95% CI 35.1–67.1), achieving the statistical superiority criteria (p = 0.0003). Patients who had TIGIT<sup>+</sup>/PD-L1<sup>+</sup> (n = 16) tended to have a numerically greater confirmed ORR (75.0% [95% CI 47.6–92.7]). After a median follow-up of 14.6 months, median progression-free survival was 7.7 months (95% CI 6.0–9.4), with a median overall survival of 17.4 months (95% CI 11.7-not reached). Treatment-related adverse events of grade ≥3 occurred in 60.0% of patients; immune-mediated adverse events of any grade was observed in 42.2%, with the majority being grade 1 or 2. In conclusion, first-line tislelizumab and ociperlimab plus GemCis yielded clinically promising tumor response and survival outcomes in advanced BTC and were generally well tolerated without new safety signals.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Subject terms:</strong> Gastrointestinal cancer, Clinical trials</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par2">Biliary tract cancer (BTC) refers to a heterogeneous and rare group of aggressive adenocarcinomas, comprising intrahepatic (ICC), gallbladder cancer (GBC), and extrahepatic cholangiocarcinoma (ECC).<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a></sup> Although BTC represents only 3% of all gastrointestinal cancers, its mortality and incidence are rising worldwide.<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup> Most patients are typically identified at a late stage, resulting in limited treatment options and a dismal prognosis, with a median overall survival (OS) reaching only 7.1 months under best supportive care.<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a></sup> Gemcitabine combined with cisplatin (GemCis) has constituted the standard first-line regimen for advanced BTC for over a decade.<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a></sup> However, despite treatment with GemCis, the median OS remains below one year, emphasizing the urgent demand for more effective therapies.<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a></sup></p>
<p id="Par3">In recent years, immunotherapy has emerged as a highly promising approach for various cancers.<sup><a href="#CR6" class="usa-link" aria-describedby="CR6">6</a></sup> In phase 3 KEYNOTE-966 and TOPAZ-1 trials of advanced BTC, adding pembrolizumab or durvalumab to GemCis significantly extended median OS compared with GemCis alone, with reported median OS of 12.7 versus 10.9 months and 12.8 versus 11.5 months, respectively.<sup><a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>,<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a></sup> However, the survival benefit of this combination therapy remains modest, highlighting an ongoing need for novel strategies to increase antitumor efficacy and prolong survival.</p>
<p id="Par4">T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT), a coinhibitory immune checkpoint receptor, is expressed on multiple tumor-infiltrating immune cells in various cancers, including natural killer (NK) cells and CD8<sup>+</sup>, helper, and regulatory T cells.<sup><a href="#CR9" class="usa-link" aria-describedby="CR9">9</a></sup> In mouse models, coblockade of TIGIT and programmed cell death-1/ligand 1 (PD-1/PD-L1) has synergistically enhanced the effector function of CD8<sup>+</sup> T cells.<sup><a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>,<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup> The CITYSCAPE and MORPHEUS-liver trials demonstrated that adding tiragolumab (a TIGIT inhibitor) to first-line atezolizumab (a PD-L1 inhibitor) or atezolizumab plus bevacizumab significantly extended median progression-free survival (PFS) and improved objective response rate (ORR) in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), respectively, with acceptable safety profiles.<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>,<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup></p>
<p id="Par5">We hypothesized that adding a TIGIT inhibitor to the existing first-line chemotherapy plus PD-1/PD-L1 inhibitor regimen could improve outcomes in BTC. Ociperlimab is an innovative humanized monoclonal IgG1 antibody that targets TIGIT with high specificity and affinity. It has also shown effective binding to complement component 1q and all Fcγ receptors, facilitating antibody-dependent cellular cytotoxicity.<sup><a href="#CR14" class="usa-link" aria-describedby="CR14">14</a></sup> A phase 1 trial of ociperlimab plus tislelizumab in patients with advanced solid tumors exhibited a manageable safety profile and promising antitumor activity.<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup> The phase 2 ZSAB-TOP study was designed to evaluate the efficacy and safety of first-line tislelizumab (a PD-1 inhibitor) plus ociperlimab and GemCis in advanced BTC.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Patient characteristics</h3>
<p id="Par6">From March 8, 2022, to January 18, 2023, 45 patients were enrolled and included in the safety analysis (SAS; Fig. <a href="#Fig1" class="usa-link">1</a>). The median age was 58.0 years (interquartile range [IQR] 53.0--64.0), with males accounting for 55.6% (25/45) of the cohort. Most patients had TNM stage IV disease (31 [68.9%]), had tumors of intrahepatic origin (34 [75.6%]), and had metastatic disease at enrollment (27 [60.0%]). A total of 44 (97.8%) patients were assessed for TIGIT and PD-L1 expression levels. The distribution of patients by TIGIT and PD-L1 status was as follows: 40.0% (18/45) were TIGIT<sup>+</sup> and PD-L1<sup>+</sup>, 4.4% (2/45) TIGIT<sup>+</sup> and PD-L1<sup>-</sup>, 28.9% (13/45) TIGIT<sup>-</sup> and PD-L1<sup>+</sup>, and 24.4% (11/45) TIGIT<sup>-</sup> and PD-L1<sup>-</sup>. The baseline characteristics of the 45 enrolled patients are detailed in Table <a href="#Tab1" class="usa-link">1</a>.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7869/12368246/a96ab253d600/41392_2025_2356_Fig1_HTML.jpg" loading="lazy" id="d33e403" height="540" width="633" alt="Fig. 1"></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Trial profile. <sup>*</sup>Four patients were excluded from the efficacy analysis set for the following reasons: one patient withdrew from the study because of loss to follow-up before the first tumor assessment; one withdrew from the study because of noncompliance with study procedures before the first tumor assessment; one discontinued treatment because of an SAE (immune-related myocarditis) before the first tumor assessment and subsequently withdrew from the study; and one discontinued treatment because of cerebral infarction before the first tumor assessment and later participated in another clinical trial</p></figcaption></figure><section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Demographics and baseline characteristics</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1">Patients (n = 45)</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Age, year</td>
<td colspan="1" rowspan="1">58.0 (53.0-64.0)</td>
</tr>
<tr><td colspan="2" rowspan="1">Sex</td></tr>
<tr>
<td colspan="1" rowspan="1"> Male</td>
<td colspan="1" rowspan="1">25 (55.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Female</td>
<td colspan="1" rowspan="1">20 (44.4)</td>
</tr>
<tr><td colspan="2" rowspan="1">Site of origin</td></tr>
<tr>
<td colspan="1" rowspan="1"> Intrahepatic</td>
<td colspan="1" rowspan="1">34 (75.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Extrahepatic</td>
<td colspan="1" rowspan="1">1 (2.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Gallbladder</td>
<td colspan="1" rowspan="1">10 (22.2)</td>
</tr>
<tr><td colspan="2" rowspan="1">Disease classification</td></tr>
<tr>
<td colspan="1" rowspan="1"> Locally advanced</td>
<td colspan="1" rowspan="1">18 (40.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Metastatic</td>
<td colspan="1" rowspan="1">27 (60.0)</td>
</tr>
<tr><td colspan="2" rowspan="1">Disease status</td></tr>
<tr>
<td colspan="1" rowspan="1"> Initially, unresectable</td>
<td colspan="1" rowspan="1">39 (86.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Recurrent</td>
<td colspan="1" rowspan="1">6 (13.3)</td>
</tr>
<tr><td colspan="2" rowspan="1">ECOG performance status</td></tr>
<tr>
<td colspan="1" rowspan="1"> 0</td>
<td colspan="1" rowspan="1">41 (91.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1</td>
<td colspan="1" rowspan="1">4 (8.9)</td>
</tr>
<tr><td colspan="2" rowspan="1">TNM disease stage</td></tr>
<tr>
<td colspan="1" rowspan="1"> II</td>
<td colspan="1" rowspan="1">2 (4.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> III</td>
<td colspan="1" rowspan="1">12 (26.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> IV<sup>*</sup>
</td>
<td colspan="1" rowspan="1">31 (68.9)</td>
</tr>
<tr><td colspan="2" rowspan="1">Expression of PD-L1 and TIGIT</td></tr>
<tr>
<td colspan="1" rowspan="1"> TIGIT<sup>+</sup> and PD-L1<sup>+</sup>
</td>
<td colspan="1" rowspan="1">18 (40.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> TIGIT<sup>+</sup> and PD-L1<sup>-</sup>
</td>
<td colspan="1" rowspan="1">2 (4.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> TIGIT<sup>-</sup> and PD-L1<sup>+</sup>
</td>
<td colspan="1" rowspan="1">13 (28.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> TIGIT<sup>-</sup> and PD-L1<sup>-</sup>
</td>
<td colspan="1" rowspan="1">11 (24.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Unknown</td>
<td colspan="1" rowspan="1">1 (2.2)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p9">
<p>Data are presented as the median (IQR) or n (%). IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; TIGIT, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain; TNM, tumor-node-metastasis; PD-L1, programmed cell death-ligand 1; PD-L1<sup>+</sup> was defined as the ratio of the area occupied by PD-L1-stained cells (tumor cells, lymphocytes, and macrophages) to the total tumor area (TAP, tumor area positivity) ≥1%; TIGIT<sup>+</sup> was defined as the percentage of TIGIT-positive immune cells relative to the total immune cell population divided by the tumor area (positive IC/tumor area), with a threshold of ≥1%</p>
<p><sup>*</sup>including 27 patients with metastatic disease at enrollment and 4 with locally advanced gallbladder cancer (T4N1M0, n = 2; T4N2M0, n = 1; T4N0M0, n = 1)</p>
</div></div></section><p id="Par7">According to the data cutoff (July 19, 2024), median follow-up was 14.6 months (IQR 9.6–19.5). Patients received a median of 8 (IQR 3.0–12.0) treatment cycles. Median exposure duration was 4.4 months (IQR 1.8–5.5) for gemcitabine, 4.1 months (IQR 1.8–5.5) for cisplatin, and 5.5 months (IQR 2.1–8.3) for tislelizumab and ociperlimab. At the data cutoff, treatment was ongoing in 3 (6.7%) of 45 patients, with 42 (93.3%) having discontinued due to disease progression (26 [57.8%] of 45 patients), patient decision (6 [13.3%]), adverse events (AEs; 5 [11.1%]), investigator decision (4 [8.9%]), or loss to follow-up (1 [2.2%]). In the efficacy analysis set (EAS), 28 (68.3%) of the 41 patients had received subsequent anticancer therapies, primarily immunotherapy (19 [46.3%]), targeted therapy (17 [41.5%]), and chemotherapy (17 [41.5%]; supplementary Table <a href="#MOESM3" class="usa-link">1</a>).</p></section><section id="Sec4"><h3 class="pmc_sec_title">Efficacy</h3>
<p id="Par8">Among the 41 patients in the EAS, the confirmed ORR evaluated by investigator was 51.2% (21 of 41 patients; 95% CI 35.1--67.1), including 3 confirmed complete responses (CRs) and 18 confirmed partial responses (PRs; Table <a href="#Tab2" class="usa-link">2</a> and Fig. <a href="#Fig2" class="usa-link">2a</a>), indicating that the combination therapy was significantly superior to the historical control (p = 0.0003). Disease control rate (DCR) was 82.9% (34 of 41 patients; 95% CI 67.9–92.8), with 13 patients exhibiting stable disease (SD; including 2 unconfirmed PR). Among the 23 patients who achieved CR or PR (including 2 unconfirmed PRs), the median duration of response (DoR) was 6.4 months (95% CI 4.2–12.5; supplementary Fig. <a href="#MOESM3" class="usa-link">1</a>). The time of treatment for all patients in the EAS is shown in Fig. <a href="#Fig2" class="usa-link">2b</a>. Three (7.3%) patients achieved obvious tumor regression after treatment, met the criteria for surgical resection, subsequently discontinued treatment and underwent curative surgery.</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Tumor response</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1">Patients (n = 41)</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">ORR (confirmed response only), n (% [95% CI])</td>
<td colspan="1" rowspan="1">21 (51.2 [95% CI, 35.1-67.1])</td>
</tr>
<tr>
<td colspan="1" rowspan="1">ORR (confirmed and unconfirmed responses), n (% [95% CI])</td>
<td colspan="1" rowspan="1">23 (56.1 [95% CI, 39.7-71.5])</td>
</tr>
<tr>
<td colspan="1" rowspan="1">DCR, n (% [95% CI])</td>
<td colspan="1" rowspan="1">34 (82.9 [95% CI, 67.9-92.8])</td>
</tr>
<tr><td colspan="2" rowspan="1">Best overall response</td></tr>
<tr>
<td colspan="1" rowspan="1"> CR</td>
<td colspan="1" rowspan="1">3 (7.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PR</td>
<td colspan="1" rowspan="1">18 (43.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> SD<sup>*</sup>
</td>
<td colspan="1" rowspan="1">13 (31.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PD</td>
<td colspan="1" rowspan="1">4 (9.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NE</td>
<td colspan="1" rowspan="1">3 (7.3)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p15"><p>Data are n (%) unless otherwise specified. ORR, objective response rate; DCR, disease control rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; CI, confidence interval; <sup>*</sup>including 2 patients with unconfirmed PR</p></div></div></section><figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12368246_41392_2025_2356_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7869/12368246/d2d14dcf7108/41392_2025_2356_Fig2_HTML.jpg" loading="lazy" id="d33e604" height="999" width="664" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Tumor responses. (<strong>a</strong>) Waterfall plot of the maximum percent change in the size of target lesions from baseline (n = 38). Three patients were excluded because of death before the first tumor response evaluation. (<strong>b</strong>) Treatment duration per Response Evaluation Criteria in Solid Tumors version 1.1 (n = 41). ICC, intrahepatic cholangiocarcinoma; GBC, gallbladder cancer; ECC, extrahepatic cholangiocarcinoma; PD-L1, programmed cell death-ligand 1; TIGIT, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain</p></figcaption></figure><p id="Par9">Patients who were TIGIT<sup>+</sup> (12 of 18 patients; 66.7% [95% CI 41.0--86.7]) or PD-L1<sup>+</sup> (17/28; 60.7% [95% CI 40.6--78.5]) presented numerically higher confirmed ORRs than those who were TIGIT<sup>-</sup> (9/22; 40.9% [95% CI 20.7--63.6]) or PD-L1<sup>-</sup> (4/12; 33.3% [95% CI 9.9--65.1]). To further explore the combined impact of TIGIT and PD-L1 status, patients were stratified on the basis of both markers. As shown in Fig. <a href="#Fig3" class="usa-link">3</a>, patients in the TIGIT<sup>+</sup> and PD-L1<sup>+</sup> subgroups (12 of 16 patients; 75.0% [95% CI 47.6–92.7]) tended to have numerically higher confirmed ORRs than those in the TIGIT<sup>+</sup> and PD-L1<sup>-</sup> (0/2; 0% [95% CI 0.0–84.2]), TIGIT<sup>-</sup> and PD-L1<sup>+</sup> (5/12; 41.7% [95% CI 15.2–72.3]), and TIGIT<sup>-</sup> and PD-L1<sup>-</sup> (4/10; 40.0% [95% CI 12.2–73.8]) subgroups. All 3 patients with confirmed CRs were positive for both TIGIT and PD-L1 expression. The confirmed ORR was 37.5% (12 of 32 patients; 95% CI 21.1--56.3) for ICC, 100.0% (8/8; 95% CI 63.1--100.0) for GBC, and 100.0% (1/1; 95% CI 2.5–100.0) for ECC. Expression of TIGIT and PD-L1 across the ICC, ECC, and GBC subgroups is provided in supplementary Table <a href="#MOESM3" class="usa-link">2</a>. A total of 28.1% (9/32) of patients with ICC were positive for both TIGIT and PD-L1, whereas 100.0% (1/1) of patients with ECC and 75.0% (6/8) of patients with GBC were positive for both TIGIT and PD-L1.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12368246_41392_2025_2356_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7869/12368246/a045ff37394a/41392_2025_2356_Fig3_HTML.jpg" loading="lazy" id="d33e709" height="872" width="750" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Subgroup analyses for the confirmed ORR in the efficacy analysis set. ORR, objective response rate; ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death-ligand 1; TIGIT, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain; CI, confidence interval</p></figcaption></figure><p id="Par10">At the data cutoff, 33 (80.5%) patients experienced PFS. The median PFS was 7.7 months (95% CI 6.0–9.4), and PFS rate at 12 months was 26.4% (95% CI 13.5–41.3; Fig. <a href="#Fig4" class="usa-link">4a</a>). At the data cutoff, 23 (56.1%) patients had died. The median OS was 17.4 months (95% CI 11.7-not reached [NR]), and OS rate at 12 months was 65.9% (95% CI 49.3–78.2; Fig. <a href="#Fig4" class="usa-link">4b</a>).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12368246_41392_2025_2356_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7869/12368246/ac8e656f71b0/41392_2025_2356_Fig4_HTML.jpg" loading="lazy" id="d33e731" height="282" width="790" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan‒Meier analyses of survival as assessed by investigators. (<strong>a</strong>) Kaplan‒Meier curves of PFS. (<strong>b</strong>) K‒M curves of OS. PFS, progression-free survival; OS, overall survival; NR, not reached; CI, confidence interval; EAS, efficacy analysis set</p></figcaption></figure><p id="Par11">We further evaluated the PFS and OS outcomes based on TIGIT and PD-L1 expression status (Supplementary Fig. <a href="#MOESM3" class="usa-link">2</a>). Specifically, the median PFS was 8.3 months (95% CI 6.0–14.6) for patients who were TIGIT<sup>+</sup> versus 7.4 months (95% CI 2.2–9.1) for TIGIT<sup>-</sup>, with median OS of NR (95% CI 17.4-NR) versus 12.9 months (95% CI 9.6–19.5). For patients who were PD-L1<sup>+</sup> versus PD-L1<sup>-</sup>, the median PFS was 8.3 months (95% CI 6.0--11.7) versus 7.0 months (95% CI 2.1--12.3), and the median OS was 19.5 months (95% CI 12.1-NR) versus 13.8 months (95% CI 6.4-NR), respectively. When TIGIT and PD-L1 status were analyzed as a combined factor, patients with TIGIT<sup>+</sup> and PD-L1<sup>+</sup> status had a median PFS of 9.4 months (95% CI 6.0–17.3), numerically greater than that of patients with TIGIT<sup>+</sup> and PD-L1<sup>-</sup> status (5.9 months [95% CI 4.2–7.6]), TIGIT<sup>-</sup> and PD-L1<sup>+</sup> status (7.7 months [95% CI 1.9–10.3]), and TIGIT<sup>-</sup> and PD-L1<sup>-</sup> status (7.0 months [95% CI 1.9–12.3]). Median OS was NR (95% CI 19.5-NR) for patients who were TIGIT<sup>+</sup> and PD-L1<sup>+</sup>, 8.1 months (95% CI 6.4–9.7) for TIGIT<sup>+</sup> and PD-L1<sup>-</sup>, 10.8 months (95% CI 1.9–15.9) for TIGIT<sup>-</sup> and PD-L1<sup>+</sup>, and 16.7 months (95% CI 5.5–NR) for TIGIT<sup>-</sup> and PD-L1<sup>-</sup>.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Safety</h3>
<p id="Par12">Treatment-emergent AE (TEAE) of any grade occurred in all patients (100.0%), with 97.8% (44 of 45 patients) reporting treatment-related AEs (TRAEs; supplementary Table <a href="#MOESM3" class="usa-link">3</a>). Grade ≥3 TRAEs occurred in 60.0% (27/45) of patients. TRAEs of grade ≥3 occurring in at least 10% of patients were neutropenia (13 [28.9%] of 45 patients), leukopenia (12 [26.7%]), thrombocytopenia (8 [17.8%]), and anemia (6 [13.3%]; Table <a href="#Tab3" class="usa-link">3</a>). Eleven (24.4%) of 45 patients experienced serious adverse events (SAEs), with 7 (15.6%) experiencing treatment-related SAEs. TRAEs resulted in chemotherapy discontinuation in 7 patients (15.6%) and immunotherapy discontinuation in 3 patients (6.7%). Three patients (6.7%) experienced TEAEs that led to death; none were deemed treatment related.</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Treatment-related adverse events occurring in ≥ 5% of patients in the safety analysis set</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">Treatment-related adverse events</th>
<th colspan="1" rowspan="1">Any grade</th>
<th colspan="1" rowspan="1">Grade ≥3</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Any event</td>
<td colspan="1" rowspan="1">44 (97.8)</td>
<td colspan="1" rowspan="1">27 (60.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Anemia</td>
<td colspan="1" rowspan="1">32 (71.1)</td>
<td colspan="1" rowspan="1">6 (13.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Leukopenia</td>
<td colspan="1" rowspan="1">31 (68.9)</td>
<td colspan="1" rowspan="1">12 (26.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Neutropenia</td>
<td colspan="1" rowspan="1">28 (62.2)</td>
<td colspan="1" rowspan="1">13 (28.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Thrombocytopenia</td>
<td colspan="1" rowspan="1">23 (51.1)</td>
<td colspan="1" rowspan="1">8 (17.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Elevated AST</td>
<td colspan="1" rowspan="1">15 (33.3)</td>
<td colspan="1" rowspan="1">3 (6.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Elevated ALT</td>
<td colspan="1" rowspan="1">14 (31.1)</td>
<td colspan="1" rowspan="1">3 (6.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Elevated serum creatinine</td>
<td colspan="1" rowspan="1">14 (31.1)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Rash</td>
<td colspan="1" rowspan="1">11 (24.4)</td>
<td colspan="1" rowspan="1">2 (4.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Proteinuria</td>
<td colspan="1" rowspan="1">9 (20.0)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Vomiting</td>
<td colspan="1" rowspan="1">7 (15.6)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Nausea</td>
<td colspan="1" rowspan="1">5 (11.1)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Urinary tract infection</td>
<td colspan="1" rowspan="1">5 (11.1)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Weight loss</td>
<td colspan="1" rowspan="1">5 (11.1)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Hypothyroidism</td>
<td colspan="1" rowspan="1">4 (8.9)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Fatigue</td>
<td colspan="1" rowspan="1">4 (8.9)</td>
<td colspan="1" rowspan="1">1 (2.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Elevated GGT</td>
<td colspan="1" rowspan="1">4 (8.9)</td>
<td colspan="1" rowspan="1">1 (2.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Elevated troponin T</td>
<td colspan="1" rowspan="1">3 (6.7)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Elevated serum bilirubin</td>
<td colspan="1" rowspan="1">3 (6.7)</td>
<td colspan="1" rowspan="1">2 (4.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Hematuria</td>
<td colspan="1" rowspan="1">3 (6.7)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Anorexia</td>
<td colspan="1" rowspan="1">3 (6.7)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p23"><p>Data are n (%) unless otherwise specified. AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase</p></div></div></section><p id="Par13">Immune-mediated AEs of any grade occurred in 19 (42.2%) patients, with dermatitis/rash (9 [20.0%] of 45 patients), hypothyroidism (4 [8.9%]), and increased troponin T (4 [8.9%]) being frequently reported (supplementary Table <a href="#MOESM3" class="usa-link">4</a>). Five (11.1%) of 45 patients experienced grade ≥3 immune-mediated AEs, including dermatitis/rash (2 [4.4%] of 45 patients), increased serum creatine phosphokinase (1 [2.2%]), thrombocytopenia (1 [2.2%]), autoimmune myocarditis (1 [2.2%]), and thrombosis (1 [2.2%]).</p>
<p id="Par14">Throughout the study, coronavirus disease 2019 (COVID-19) occurred in 23 (51.1%) patients (any grade, n = 23; grade ≥3, n = 1); none were deemed treatment related. Nineteen patients experienced 20 treatment delays due to COVID-19 positivity or related isolation/lockdown measures, with a median delay of 9.0 days (range 1.0–19.0). Additionally, four patients skipped one treatment cycle because they were positive for COVID-19.</p></section></section><section id="Sec6"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par15">To our knowledge, ZSAB-TOP is the first study evaluating the efficacy and safety of adding a TIGIT inhibitor to the standard combination of a PD-1 inhibitor and GemCis in advanced BTC. Our results demonstrated that the combination of ociperlimab, tislelizumab, and GemCis yielded a remarkable ORR of 51.2%, which was statistically significantly greater than the historical ORR of 25% for GemCis (p = 0.0003),<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>,<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup> the standard care at the time of the study design of ZSAB-TOP. Additionally, the combination therapy exhibited a clinically promising OS of 17.4 months, indicating that the tumor response to the combination therapy may lead to long-term survival benefits. Dual immunotherapy plus GemCis was generally well tolerated, with an incidence of 60.0% (32/45) for grade ≥3 TRAEs.</p>
<p id="Par16">Global phase 3 KEYNOTE-966 and TOPAZ-1 trials established pembrolizumab or durvalumab plus GemCis as new first-line standards, but the ORR was only marginally higher (26.7% and 29.0%, respectively) than that of GemCis,<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>,<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup> reinforcing the significance of the improved ORR observed in ZSAB-TOP with the addition of ociperlimab to standard chemoimmunotherapy. Moreover, the OS observed in our study was also numerically longer than that with durvalumab or pembrolizumab combined with GemCis, with median OS times of 12.8 months and 12.7 months, respectively.<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>,<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup> However, caution is needed when interpreting these results, with the limitations of cross-sectional comparisons. Specifically, differences in patient disease and demographics characteristics exist between the ZSAB-TOP and KEYNOTE-966 or TOPAZ-1 trials,<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>,<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup> including a lower median age, better Eastern Cooperative Oncology Group (ECOG) performance status, and fewer patients with metastatic disease, indicating that potentially younger and medically fitter patients with relatively lower disease burdens are included in our study. Nevertheless, the encouraging treatment response and survival outcomes suggest the potential of this combination for advanced BTC, and additional research is required to confirm these findings.</p>
<p id="Par17">In addition to between-trial differences, which necessitate caution in cross-trial comparisons, one possible explanation for the improved outcomes could be the addition of TIGIT inhibition to the immunotherapy regimen. First, TIGIT inhibitors can directly modulate immune-mediated antitumor activity. Mechanistically, TIGIT inhibits the cytotoxic activity of NK/T cells through competitive antagonism of CD226-driven activation. Through this competition, TIGIT suppresses the activation, migration, and cytotoxic functions of NK/T cells while facilitating their exhaustion. Furthermore, TIGIT may alter T-cell metabolism to increase tumor cell invasion, angiogenesis, and colony formation.<sup><a href="#CR18" class="usa-link" aria-describedby="CR18">18</a></sup> Second, TIGIT has indirect inhibitory effects on the tumor microenvironment. By triggering CD155, TIGIT induces increased interleukin (IL)-10 secretion while reducing IL-12 levels and modulates T-cell proliferation alongside the release of immunostimulatory cytokines, such as interferon-gamma.<sup><a href="#CR18" class="usa-link" aria-describedby="CR18">18</a></sup> On the basis of these two points, inhibiting TIGIT could enhance the cytotoxic activities of NK/T cells. Third, TIGIT inhibitors can act synergistically with PD-1/PD-L1 blockades, enhancing their antitumor activities. TIGIT is frequently coexpressed with PD-1 across various T-cell subsets, and PD-1 inhibition has been reported to elevate TIGIT levels on CD8<sup>+</sup> T cells by up to 1.5-fold. The increased expression of coinhibitory molecules, including lymphocyte-activation gene 3, TIGIT, and V domain immunoglobulin suppressor of T-cell activation, plays a critical role in T-cell dysfunction and treatment resistance, suggesting that dual TIGIT and PD-1 blockade may improve outcomes over PD-1 monotherapy. Overall, TIGIT inhibitors could enhance NK/T-cell antitumor activity by disrupting the TIGIT signaling pathway. Additionally, the unique properties of tislelizumab may also contribute to these favorable results. Tislelizumab differs from other PD-1 inhibitors by having an engineered Fc region that abolishes antibody-dependent cellular phagocytosis (a potential resistance mechanism to anti-PD-1 therapy), which may promote a high ORR and durable tumor responses.<sup><a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a></sup> The PFS observed in ZSAB-TOP was numerically comparable to those in the KEYNOTE-966 and TOPAZ-1 trials, potentially due to complexities involved in assessing PFS in patients with BTC. Progression assessment in this population frequently depends on nonradiographic indicators, including serum carbohydrate antigen 19-9 expression, liver function, and biliary obstruction. Thus, PFS evaluated per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 may not fully capture disease progression in patients with BTC.</p>
<p id="Par18">Recently, dual immunotherapy targeting PD-1/PD-L1 and TIGIT has yielded promising antitumor activity in other solid tumors, including NSCLC and HCC.<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>,<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup> For example, the CITYSCAPE trial demonstrated that first-line atezolizumab plus tiragolumab led to clinically meaningful improvements in PFS (5.4 months <em>vs</em> 3.6 months) and ORR (31.3% <em>vs</em> 16.2%) over atezolizumab alone in PD-L1-selected NSCLC.<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a></sup> Notably, Atezolizumab plus tiragolumab showed a marked OS benefit in patients exhibiting high PD-L1 expression (tumor proportion score ≥50%), suggesting that dual blockade with a TIGIT inhibitor may enhance treatment outcomes of PD-1/PD-L1 inhibitors in tumors exhibiting elevated PD-L1 levels.<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a></sup> Conversely, in the phase 3 SKYSCRAPER-02 trial, tiragolumab plus atezolizumab and chemotherapy did not lead to improvements in PFS and OS in treatment-naïve patients with extensive-stage small-cell lung cancer (SCLC), a disease typically associated with lower PD-L1 expression than NSCLC.<sup><a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>,<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a></sup> Although this exploration in SCLC was unsuccessful, it further underscores the possible impact of PD-L1 and TIGIT expression in therapeutic effects. Since PD-1/PD-L1 and TIGIT are upregulated on infiltrating CD8<sup>+</sup> T cells in BTC, dual immunotherapy is worth exploring in this disease population.<sup><a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>,<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup> Our previous research also found that high PD-L1 and TIGIT dual expression linked to worse OS in patients with ICC (Pei YZ et al., Zhongshan Hospital, Fudan University, unpublished data; supplementary Fig. <a href="#MOESM3" class="usa-link">3</a>), suggesting that combined anti-TIGIT and PD-L1 therapy may represent a promising approach for treating ICC. In support of this hypothesis, our study revealed that patients who were either TIGIT<sup>+</sup> or PD-L1<sup>+</sup> presented numerically higher confirmed ORR, PFS, and OS rates, especially those positive for both markers. Notably, all patients who achieved confirmed CR were in the TIGIT<sup>+</sup> and PD-L1<sup>+</sup> subgroups. Consistent with previous reports, our study revealed that TIGIT was associated with PD-L1 expression, with 90% of TIGIT-positive patients also being PD-L1 positive.<sup><a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>–<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a></sup> Overall, coexpression of TIGIT and PD-L1 might help identify better responders to TIGIT and PD-L1 inhibitors plus chemotherapy in BTC. Additional research is necessary to confirm these findings. Currently, several phase 3 trials investigating dual PD-1 and TIGIT blockade in BTC are underway (<a href="https://clinicaltrials.gov/ct2/show/NCT06467357" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06467357</a> and <a href="https://clinicaltrials.gov/ct2/show/NCT06109779" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06109779</a>) and may provide further information regarding this combination strategy.</p>
<p id="Par19">Studies on advanced BTC frequently pool various subtypes together; however, differences in treatment response and prognosis warrant further investigation. Subgroup analyses from the KEYNOTE-966 and TOPAZ-1 trials revealed that immunotherapy combined with chemotherapy yielded comparable efficacy across the ICC, ECC, and GBC subgroups.<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>,<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup> In the present study, GBC and ECC patients tended to have better tumor responses. All patients with GBC (n = 8) and ECC (n = 1) achieved an objective response, whereas 37.5% of those with ICC achieved an objective response. Interestingly, up to 77.8% of patients with GBC and ECC were positive for both TIGIT and PD-L1, whereas 28.1% of the ICC patients were dual-positive. Although limited by a small sample size, these results suggested that PD-L1 and TIGIT were more likely to be coexpressed in the GBC and ECC subtypes and that dual inhibition of these targets may have synergistic benefits in these subtypes. Further explorations into PD-L1 and TIGIT expression, as well as the efficacy of dual PD-L1 and TIGIT blockade in these subtypes, are warranted.</p>
<p id="Par20">The combination of tislelizumab, ociperlimab, and GemCis exhibited manageable safety, with grade ≥3 TRAEs in 60.0% of patients, comparable to that in the TOPAZ-1 (62.7%) and KEYNOTE-966 (70.0%) trials.<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>,<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup> Notably, most of these AEs were controllable through dose discontinuation or appropriate supportive care, and no treatment-related deaths occurred. Hematologic toxicities, such as neutropenia, leukopenia, thrombocytopenia, and anemia, were the most common grade ≥3 TRAEs, aligning with the known profiles of GemCis.<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>,<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup> Additionally, 42.2% of patients experienced immune-mediated AEs, which was comparable to the percentage of patients receiving dual immunotherapy combining TIGIT and PD-L1 inhibitors (21.9%-54.4%).<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>,<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a></sup> The most frequently reported immune-mediated AEs included dermatitis/rash, hypothyroidism, and increased troponin T, in line with previous findings for tislelizumab and ociperlimab combination therapy.<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup> Most of these AEs were grade 1–2, with no new safety signals.<sup><a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>,<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a></sup> Importantly, only 3 (6.7%) patients discontinued immunotherapy because of TRAEs. Overall, the safety profile of tislelizumab plus ociperlimab and GemCis was probably acceptable for patients with advanced BTC, without increasing the incidence of grade ≥3 TRAEs or treatment discontinuation relative to the TOPAZ-1 and KEYNOTE-966 trials.<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>,<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup></p>
<p id="Par21">The current study had several limitations. First, even though ZSAB-TOP was designed with a prespecified statistical hypothesis and sample size calculation, caution was warranted when concluding the superiority of our combination therapy over GemCis, the standard care when study design of ZSAB-TOP, on the basis of its single-arm design. Moreover, although the TOPAZ-1 and KEYNOTE-966 trials exhibited significantly improved PFS and OS with GemCis plus durvalumab or pembrolizumab over GemCis alone, the ORR remained similar. Second, the confirmed ORR, as assessed by the investigator, served as the primary endpoint. However, to minimize potential bias and ensure consistency, response assessments were rechecked by the leading principal investigator at the primary center after evaluations by investigators at each study site. Third, the study was carried out in the context of COVID-19 pandemic, which has impacted patient enrollment and treatment, resulting in challenges such as treatment discontinuation and delays due to constrained access to medical visits, potentially introducing bias. Fourth, the lack of molecular profiling data represents another limitation of our study. Given that molecular alterations such as isocitrate dehydrogenase 1 (<em>IDH1</em>) mutations or fibroblast growth factor receptor 2 (<em>FGFR2</em>) fusions may influence therapeutic outcomes, the presence of such genomic heterogeneity could have affected the results, particularly in the context of a relatively small cohort.<sup><a href="#CR31" class="usa-link" aria-describedby="CR31">31</a></sup> Furthermore, the study population was exclusively Asian, limiting the generalizability of the findings to other racial and ethnic groups. Therefore, randomized controlled trials with larger and more diverse cohorts are warranted to confirm these findings.</p>
<p id="Par22">In conclusion, tislelizumab plus ociperlimab and GemCis yielded clinically promising antitumor activity and survival outcomes in patients with advanced BTC, with a manageable safety profile. These findings underscore that this combination strategy may serve as a potential feasible and optimized first-line treatment option for advanced BTC. Prospective validation in large-scale, phase 3 randomized controlled trials is warranted to confirm these results and inform future clinical practice.</p></section><section id="Sec7"><h2 class="pmc_sec_title">Materials and methods</h2>
<section id="Sec8"><h3 class="pmc_sec_title">Ethics</h3>
<p id="Par23">The protocol received approval from the institutional review board at each participating center, and the study was conducted in line with local regulations, Good Clinical Practice guidelines, and Declaration of Helsinki. Data from this trial are available upon request to regulatory health authorities, the sponsor’s monitors/representatives, and institutional review board or ethics committee members. An independent clinical research organization and a site management organization were responsible for study management and quality monitoring. Regular site visits, data verification, and compliance checks were performed throughout the study. All participants gave written informed consent before enrollment. This study is registered with ClinicalTrials.gov, number <a href="https://clinicaltrials.gov/ct2/show/NCT05023109" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05023109</a>.</p></section><section id="Sec9"><h3 class="pmc_sec_title">Study design and participants</h3>
<p id="Par24">ZSAB-TOP is a single-arm, investigator-initiated, phase 2 trial recruiting patients from 3 centers in China (supplementary data). Eligible patients aged 18–75 years with histologically or cytologically confirmed unresectable advanced BTC (GBC, ICC, or ECC) were included. Additional primary inclusion criteria included at least one measurable target lesion per RECIST version 1.1, an estimated life expectancy of at least 3 months, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ and bone marrow function. The key exclusion criteria were ampullary cancer or mixed hepatocellular and cholangiocellular carcinoma, previous systemic therapy (such as chemotherapy or immunotherapy) for BTC, known hypersensitivity or allergy reaction to study treatments, history of another malignancy, or active autoimmune disease necessitating systemic treatment. Detailed inclusion and exclusion criteria can be found in the trial protocol.</p></section><section id="Sec10"><h3 class="pmc_sec_title">Procedures</h3>
<p id="Par25">The treatment regimen consisted of intravenous tislelizumab (200 mg) and ociperlimab (900 mg) given on day 1, plus gemcitabine (1000 mg/m²) and cisplatin (25 mg/m²) administered on days 1 and 8 of a 21-day cycle. GemCis was given for a maximum of eight cycles unless disease progression occurred. Tislelizumab and ociperlimab administration continued until unacceptable toxicity, investigator decision, disease progression, death, or withdrawal of consent, whichever occurred first. Dose reductions for tislelizumab and ociperlimab were not permitted, while temporary dose interruptions of up to 12 weeks were allowed to manage AEs related to tislelizumab or ociperlimab, necessitating a delay for both drugs. If the AEs failed to resolve within 12 weeks, tislelizumab and ociperlimab were permanently discontinued. Patients who discontinued tislelizumab and ociperlimab due to unacceptable toxicity were allowed to continue GemCis, and vice versa. Treatment decision criteria, including interruption, discontinuation, and dose reduction for AEs, are detailed in the study protocol.</p>
<p id="Par26">Baseline and follow-up tumor assessments were conducted via computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen, chest, and pelvis every 9 weeks until withdrawal of consent, death, disease progression, loss to follow-up, or study completion, whichever occurred first. Response assessments were performed by investigators at each study site via RECIST version 1.1 and subsequently reviewed by the leading principal investigator at the primary center to ensure consistency. CR or PR was verified by a subsequent CT scan or MRI performed 4–6 weeks following the initial response. Post-treatment survival follow-ups were conducted every 3 months until study completion, death, withdrawal of consent, or loss to follow-up. AEs were recorded during the whole study and for 30 days following the final dose of the study drug (90 days for immune-mediated AEs) or until patients began another anticancer treatment. The severity of the AEs was graded via the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.</p>
<p id="Par27">Tumor biopsy samples, either fresh or formalin-fixed and paraffin-embedded, were acquired from all patients for central laboratory evaluation of TIGIT and PD-L1 expression via TIGIT (E5Y1W; #99567S; Cell Signaling Technology, Danvers, MA, USA) and VENTANA PD-L1 (SP263; Roche, Switzerland) antibodies, respectively. The optimal cutoff points for evaluating PD-L1 and TIGIT expression were identified via receiver operating characteristic curve analysis. A sample was considered to be PD-L1 positive (PD-L1<sup>+</sup>) if the tumor area positivity (TAP) was 1% or higher. TAP was calculated as the ratio of the area occupied by PD-L1-stained cells (macrophages, tumor cells, and lymphocytes) to the total tumor area. TIGIT positivity (TIGIT<sup>+</sup>) was calculated as the percentage of TIGIT-stained immune cells relative to total immune cells divided by the tumor area, with a threshold of ≥1%.</p></section><section id="Sec11"><h3 class="pmc_sec_title">Outcomes</h3>
<p id="Par28">The primary endpoint was investigator-assessed confirmed ORR (proportion of CR/PR) by RECIST version 1.1. The secondary endpoints included the DCR (CR/PR/SD at the best overall response), DoR (time interval from first documented CR/PR to death from any cause or disease progression), PFS (time interval from the first dose of study treatment until death from any cause or disease progression) according to RECIST version 1.1, OS (time interval from the first dose of study treatment until death from any cause), and safety. Exploratory endpoint was association of the clinical response with PD-L1 and TIGIT expression.</p></section><section id="Sec12"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par29">At the time of the study design, GemCis was recognized as the standard first-line regimen for unresectable BTC, yielding an ORR of 25% in advanced cases.<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>,<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup> Sample size was estimated using an exact binomial test with a one-sided alpha of 0.05 and 80% power to test the hypothesis that the combination therapy would increase ORR from 25% to 45%. Accounting for an anticipated 20% dropout rate, the total planned enrollment was set at 45 patients.</p>
<p id="Par30">Efficacy was assessed in the EAS, defined as patients who received at least one dose of drugs and had at least one posttreatment tumor assessment, unless treatment was discontinued owing to clinical progression or death before the first posttreatment tumor assessment. All patients who received at least one dose of any study drug were included in the SAS for safety evaluation.</p>
<p id="Par31">The investigator-assessed tumor responses were summarized descriptively, along with their corresponding 95% CIs, which were calculated via the Clopper‒Pearson method. The Kaplan‒Meier method was used to estimate the medians of investigator-assessed PFS, DoR, and OS, and the Brookmeyer‒Crowley method was used to calculate the 95% CIs. Greenwood’s formula was applied to estimate the 95% CIs for the 6- and 12-month PFS and OS rates. Post hoc subgroup analyses of the ORR based on age (&lt;65 years or ≥65 years), ECOG performance status (0 or 1), site of origin (ICC, ECC, or GBC), sex (female or male), disease classification (locally advanced or metastatic), disease status (initially unresectable or recurrent), TIGIT<sup>+</sup> status (PD-L1<sup>+</sup> or PD-L1<sup>-</sup>), and TIGIT<sup>-</sup> status (PD-L1<sup>+</sup> or PD-L1<sup>-</sup>) were performed descriptively.</p>
<p id="Par32">Statistical analyses were conducted via SAS Software (version 9.4; SAS Institute Inc., Cary, NC, USA). A p value below 0.05 was regarded as statistically significant.</p></section></section><section id="Sec13"><h2 class="pmc_sec_title">Supplementary information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12368246/bin/41392_2025_2356_MOESM1_ESM.doc" data-ga-action="click_feat_suppl" class="usa-link">Statistical Analysis Plan</a><sup> (169KB, doc) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12368246/bin/41392_2025_2356_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">CONSORT_2025_editable_checklist</a><sup> (34.1KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM3"><div class="media p"><div class="caption">
<a href="/articles/instance/12368246/bin/41392_2025_2356_MOESM3_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Sigtrans_Supplementary_Materials</a><sup> (4.2MB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM4"><div class="media p"><div class="caption">
<a href="/articles/instance/12368246/bin/41392_2025_2356_MOESM4_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Study protocol</a><sup> (551.8KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>This study was supported by the Program of Shanghai Academic Research Leader (22XD1402700) and BeiGene (Beijing) Co., Ltd. We would like to thank the investigators, the site support staff, and especially the patients for participating in this study.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>J.F., J.Z., and G.S. contributed to the conception and design of the work. G.S., X.H., L.M., H.L., J.Z., J.W., Q.G., X.G., S.Q., H.S., Y.S., X.H., X.W., Y.Y., X.Z., C.H., Z.D., Y.C., Y.H., Y.S., and Q.S. contributed to the acquisition of the data. G.S., X.H., L.M., and JW contributed to the data analysis and visualization. J.F., J.Z., and G.S. contributed to the interpretation of the data. G.S., X.H., L.M., and H.L. drafted the manuscript. All the authors were involved in patient and data management, conceived and (locally) supervised the study, and revised the manuscript. All the authors read and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Data availability</h2>
<p>The datasets supporting the findings of the current study are included in the manuscript and its Supplemental Materials. The datasets are available from the corresponding author upon reasonable request.</p></section><section id="FPar1"><h2 class="pmc_sec_title">Competing interests</h2>
<p id="Par33">The authors declare that they have no competing interests.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1"><p><strong>Publisher’s note</strong> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>
<div class="fn p" id="fn2"><p>These authors contributed equally: Guoming Shi, Xiaoyong Huang, Liang Ma, Hui Li</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Guoming Shi, Email: shi.guoming@zs-hospital.sh.cn.</p>
<p>Jian Zhou, Email: zhou.jian@zs-hospital.sh.cn.</p>
<p>Jia Fan, Email: fan.jia@zs-hospital.sh.cn.</p></section><section id="sec14"><h2 class="pmc_sec_title">Supplementary information</h2>
<p>The online version contains supplementary material available at 10.1038/s41392-025-02356-y.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y. &amp; Zhu, A. X. Biliary tract cancer. <em>Lancet</em><strong>397</strong>, 428–444 (2021).
</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)00153-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33516341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Valle,%20J.%20W.,%20Kelley,%20R.%20K.,%20Nervi,%20B.,%20Oh,%20D.%20Y.%20&amp;%20Zhu,%20A.%20X.%20Biliary%20tract%20cancer.%20Lancet397,%20428%E2%80%93444%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Chen, S. et al. Current status, trends, and predictions in the burden of gallbladder and biliary tract cancer in China from 1990 to 2019. <em>Chin. Med J. (Engl.)</em><strong>135</strong>, 1697–1706 (2022).
</cite> [<a href="https://doi.org/10.1097/CM9.0000000000002258" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9509182/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35984211/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen,%20S.%20et%20al.%20Current%20status,%20trends,%20and%20predictions%20in%20the%20burden%20of%20gallbladder%20and%20biliary%20tract%20cancer%20in%20China%20from%201990%20to%202019.%20Chin.%20Med%20J.%20(Engl.)135,%201697%E2%80%931706%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Ji, J. H. et al. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). <em>Jpn J. Clin. Oncol.</em><strong>45</strong>, 256–260 (2015).
</cite> [<a href="https://doi.org/10.1093/jjco/hyu210" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25628352/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ji,%20J.%20H.%20et%20al.%20Natural%20history%20of%20metastatic%20biliary%20tract%20cancer%20(BTC)%20patients%20with%20good%20performance%20status%20(PS)%20who%20were%20treated%20with%20only%20best%20supportive%20care%20(BSC).%20Jpn%20J.%20Clin.%20Oncol.45,%20256%E2%80%93260%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. <em>N. Engl. J. Med</em><strong>362</strong>, 1273–1281 (2010).
</cite> [<a href="https://doi.org/10.1056/NEJMoa0908721" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20375404/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Valle,%20J.%20et%20al.%20Cisplatin%20plus%20gemcitabine%20versus%20gemcitabine%20for%20biliary%20tract%20cancer.%20N.%20Engl.%20J.%20Med362,%201273%E2%80%931281%20(2010)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Park, J. O. et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. <em>Cancer Res Treat.</em><strong>47</strong>, 343–361 (2015).
</cite> [<a href="https://doi.org/10.4143/crt.2014.308" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4509359/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25989801/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Park,%20J.%20O.%20et%20al.%20Gemcitabine%20Plus%20Cisplatin%20for%20Advanced%20Biliary%20Tract%20Cancer:%20A%20Systematic%20Review.%20Cancer%20Res%20Treat.47,%20343%E2%80%93361%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Zhao, Y., Yang, M., Feng, J., Wang, X. &amp; Liu, Y. Advances in immunotherapy for biliary tract cancers. <em>Chin. Med J. (Engl.)</em><strong>137</strong>, 524–532 (2024).
</cite> [<a href="https://doi.org/10.1097/CM9.0000000000002759" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10932537/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37646139/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao,%20Y.,%20Yang,%20M.,%20Feng,%20J.,%20Wang,%20X.%20&amp;%20Liu,%20Y.%20Advances%20in%20immunotherapy%20for%20biliary%20tract%20cancers.%20Chin.%20Med%20J.%20(Engl.)137,%20524%E2%80%93532%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Oh, D. Y. et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomized phase 3 study. <em>Lancet Gastroenterol. Hepatol.</em><strong>9</strong>, 694–704 (2024).
</cite> [<a href="https://doi.org/10.1016/S2468-1253(24)00095-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38823398/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oh,%20D.%20Y.%20et%20al.%20Durvalumab%20or%20placebo%20plus%20gemcitabine%20and%20cisplatin%20in%20participants%20with%20advanced%20biliary%20tract%20cancer%20(TOPAZ-1):%20updated%20overall%20survival%20from%20a%20randomized%20phase%203%20study.%20Lancet%20Gastroenterol.%20Hepatol.9,%20694%E2%80%93704%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomized, double-blind, placebo-controlled, phase 3 trial. <em>Lancet</em><strong>401</strong>, 1853–1865 (2023).
</cite> [<a href="https://doi.org/10.1016/S0140-6736(23)00727-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37075781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kelley,%20R.%20K.%20et%20al.%20Pembrolizumab%20in%20combination%20with%20gemcitabine%20and%20cisplatin%20compared%20with%20gemcitabine%20and%20cisplatin%20alone%20for%20patients%20with%20advanced%20biliary%20tract%20cancer%20(KEYNOTE-966):%20a%20randomized,%20double-blind,%20placebo-controlled,%20phase%203%20trial.%20Lancet401,%201853%E2%80%931865%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Ge, Z., Peppelenbosch, M. P., Sprengers, D. &amp; Kwekkeboom, J. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. <em>Front Immunol.</em><strong>12</strong>, 699895 (2021).
</cite> [<a href="https://doi.org/10.3389/fimmu.2021.699895" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8339559/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34367161/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ge,%20Z.,%20Peppelenbosch,%20M.%20P.,%20Sprengers,%20D.%20&amp;%20Kwekkeboom,%20J.%20TIGIT,%20the%20Next%20Step%20Towards%20Successful%20Combination%20Immune%20Checkpoint%20Therapy%20in%20Cancer.%20Front%20Immunol.12,%20699895%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Banta, K. L. et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates coblockade to optimize anti-tumor CD8(+) T cell responses. <em>Immunity</em><strong>55</strong>, 512–526.e519 (2022).
</cite> [<a href="https://doi.org/10.1016/j.immuni.2022.02.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9287124/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35263569/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Banta,%20K.%20L.%20et%20al.%20Mechanistic%20convergence%20of%20the%20TIGIT%20and%20PD-1%20inhibitory%20pathways%20necessitates%20coblockade%20to%20optimize%20anti-tumor%20CD8(+)%20T%20cell%20responses.%20Immunity55,%20512%E2%80%93526.e519%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T-cell effector function. <em>Cancer Cell</em><strong>26</strong>, 923–937 (2014).
</cite> [<a href="https://doi.org/10.1016/j.ccell.2014.10.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25465800/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Johnston,%20R.%20J.%20et%20al.%20The%20immunoreceptor%20TIGIT%20regulates%20antitumor%20and%20antiviral%20CD8(+)%20T-cell%20effector%20function.%20Cancer%20Cell26,%20923%E2%80%93937%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Cho, B. C. et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomized, double-blind, phase 2 study. <em>Lancet Oncol.</em><strong>23</strong>, 781–792 (2022).
</cite> [<a href="https://doi.org/10.1016/S1470-2045(22)00226-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35576957/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cho,%20B.%20C.%20et%20al.%20Tiragolumab%20plus%20atezolizumab%20versus%20placebo%20plus%20atezolizumab%20as%20a%20first-line%20treatment%20for%20PD-L1-selected%20non-small%20cell%20lung%20cancer%20(CITYSCAPE):%20primary%20and%20follow-up%20analyses%20of%20a%20randomized,%20double-blind,%20phase%202%20study.%20Lancet%20Oncol.23,%20781%E2%80%93792%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Finn, R. S. et al. The results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC). <em>J. Clin. Oncol.</em><strong>41</strong>, 4010–4010 (2023).</cite> [<a href="https://scholar.google.com/scholar_lookup?Finn,%20R.%20S.%20et%20al.%20The%20results%20from%20the%20MORPHEUS-liver%20study:%20Phase%20Ib/II%20randomized%20evaluation%20of%20tiragolumab%20(tira)%20in%20combination%20with%20atezolizumab%20(atezo)%20and%20bevacizumab%20(bev)%20in%20patients%20with%20unresectable,%20locally%20advanced%20or%20metastatic%20hepatocellular%20carcinoma%20(uHCC).%20J.%20Clin.%20Oncol.41,%204010%E2%80%934010%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Chen, X. et al. A Fc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models. <em>J. Cancer Res</em><strong>81</strong>, 1854 (2021).</cite> [<a href="https://doi.org/10.3389/fimmu.2022.828319" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8902820/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35273608/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen,%20X.%20et%20al.%20A%20Fc-competent%20anti-human%20TIGIT%20blocking%20antibody%20BGB-A1217%20elicits%20strong%20immune%20responses%20and%20potent%20anti-tumor%20efficacy%20in%20pre-clinical%20models.%20J.%20Cancer%20Res81,%201854%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Frentzas, S. et al. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors. <em>J. Immunother. Cancer</em><strong>11</strong>, e005829 (2023).
</cite> [<a href="https://doi.org/10.1136/jitc-2022-005829" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10603446/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37857528/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Frentzas,%20S.%20et%20al.%20AdvanTIG-105:%20a%20phase%20I%20dose%20escalation%20study%20of%20the%20anti-TIGIT%20monoclonal%20antibody%20ociperlimab%20in%20combination%20with%20tislelizumab%20in%20patients%20with%20advanced%20solid%20tumors.%20J.%20Immunother.%20Cancer11,%20e005829%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Okusaka, T. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in Japan. <em>Br. J. Cancer</em><strong>103</strong>, 469–474 (2010).
</cite> [<a href="https://doi.org/10.1038/sj.bjc.6605779" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2939781/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20628385/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Okusaka,%20T.%20et%20al.%20Gemcitabine%20alone%20or%20in%20combination%20with%20cisplatin%20in%20patients%20with%20biliary%20tract%20cancer:%20a%20comparative%20multicenter%20study%20in%20Japan.%20Br.%20J.%20Cancer103,%20469%E2%80%93474%20(2010)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Oh, D. Y. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. <em>NEJM Evid.</em><strong>1</strong>, EVIDoa2200015 (2022).
</cite> [<a href="https://doi.org/10.1056/EVIDoa2200015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38319896/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oh,%20D.%20Y.%20et%20al.%20Durvalumab%20plus%20Gemcitabine%20and%20Cisplatin%20in%20Advanced%20Biliary%20Tract%20Cancer.%20NEJM%20Evid.1,%20EVIDoa2200015%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Chu, X., Tian, W., Wang, Z., Zhang, J. &amp; Zhou, R. Coinhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials. <em>Mol. Cancer</em><strong>22</strong>, 93 (2023).
</cite> [<a href="https://doi.org/10.1186/s12943-023-01800-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10249258/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37291608/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chu,%20X.,%20Tian,%20W.,%20Wang,%20Z.,%20Zhang,%20J.%20&amp;%20Zhou,%20R.%20Coinhibition%20of%20TIGIT%20and%20PD-1/PD-L1%20in%20Cancer%20Immunotherapy:%20Mechanisms%20and%20Clinical%20Trials.%20Mol.%20Cancer22,%2093%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Ren, Z. et al. Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. <em>Liver Cancer</em><strong>12</strong>, 72–84 (2023).
</cite> [<a href="https://doi.org/10.1159/000527175" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9982342/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36872927/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ren,%20Z.%20et%20al.%20Tislelizumab%20in%20Patients%20with%20Previously%20Treated%20Advanced%20Hepatocellular%20Carcinoma%20(RATIONALE-208):%20A%20Multicenter,%20Non-Randomized,%20Open-Label,%20Phase%202%20Trial.%20Liver%20Cancer12,%2072%E2%80%9384%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Qin, S. et al. Tislelizumab <em>vs</em> Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. <em>JAMA Oncol.</em><strong>9</strong>, 1651–1659 (2023).
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2023.4003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10557031/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37796513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qin,%20S.%20et%20al.%20Tislelizumab%20vs%20Sorafenib%20as%20First-Line%20Treatment%20for%20Unresectable%20Hepatocellular%20Carcinoma:%20A%20Phase%203%20Randomized%20Clinical%20Trial.%20JAMA%20Oncol.9,%201651%E2%80%931659%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Zhang, T. et al. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. <em>Cancer Immunol. Immunother.</em><strong>67</strong>, 1079–1090 (2018).
</cite> [<a href="https://doi.org/10.1007/s00262-018-2160-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6006217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29687231/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang,%20T.%20et%20al.%20The%20binding%20of%20an%20anti-PD-1%20antibody%20to%20Fc%CE%B3R%CE%99%20has%20a%20profound%20impact%20on%20its%20biological%20functions.%20Cancer%20Immunol.%20Immunother.67,%201079%E2%80%931090%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Rudin, C. M. et al. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. <em>J. Clin. Oncol.</em><strong>42</strong>, 324–335 (2024).
</cite> [<a href="https://doi.org/10.1200/JCO.23.01363" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10824371/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37976444/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rudin,%20C.%20M.%20et%20al.%20SKYSCRAPER-02:%20Tiragolumab%20in%20Combination%20With%20Atezolizumab%20Plus%20Chemotherapy%20in%20Untreated%20Extensive-Stage%20Small-Cell%20Lung%20Cancer.%20J.%20Clin.%20Oncol.42,%20324%E2%80%93335%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Acheampong, E. et al. Tumor PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <em>Cells</em><strong>9</strong>, (2020).</cite> [<a href="https://doi.org/10.3390/cells9112393" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7693331/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33142852/" class="usa-link">PubMed</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Shi, X. et al. Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. <em>NPJ Precis Oncol.</em><strong>6</strong>, 58 (2022).
</cite> [<a href="https://doi.org/10.1038/s41698-022-00300-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9388673/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35982235/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shi,%20X.%20et%20al.%20Single-cell%20atlas%20of%20diverse%20immune%20populations%20in%20the%20advanced%20biliary%20tract%20cancer%20microenvironment.%20NPJ%20Precis%20Oncol.6,%2058%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Qiao, Y. et al. Enhancement of CAR-T-cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. <em>Cancer Commun. (Lond.)</em><strong>43</strong>, 788–807 (2023).
</cite> [<a href="https://doi.org/10.1002/cac2.12452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10354409/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37282786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qiao,%20Y.%20et%20al.%20Enhancement%20of%20CAR-T-cell%20activity%20against%20cholangiocarcinoma%20by%20simultaneous%20knockdown%20of%20six%20inhibitory%20membrane%20proteins.%20Cancer%20Commun.%20(Lond.)43,%20788%E2%80%93807%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Chauvin, J. M. et al. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. <em>J. Clin. Invest</em><strong>125</strong>, 2046–2058 (2015).
</cite> [<a href="https://doi.org/10.1172/JCI80445" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4463210/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25866972/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chauvin,%20J.%20M.%20et%20al.%20TIGIT%20and%20PD-1%20impair%20tumor%20antigen-specific%20CD8%E2%81%BA%20T%20cells%20in%20melanoma%20patients.%20J.%20Clin.%20Invest125,%202046%E2%80%932058%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Han, H. S. et al. TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by coblockade of PD-1 and TIGIT in bladder cancer. <em>Cancer Lett.</em><strong>499</strong>, 137–147 (2021).
</cite> [<a href="https://doi.org/10.1016/j.canlet.2020.11.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33249194/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Han,%20H.%20S.%20et%20al.%20TOX-expressing%20terminally%20exhausted%20tumor-infiltrating%20CD8(+)%20T%20cells%20are%20reinvigorated%20by%20coblockade%20of%20PD-1%20and%20TIGIT%20in%20bladder%20cancer.%20Cancer%20Lett.499,%20137%E2%80%93147%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Li, X. et al. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. <em>Front Oncol.</em><strong>9</strong>, 1066 (2019).
</cite> [<a href="https://doi.org/10.3389/fonc.2019.01066" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6823747/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31709176/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li,%20X.%20et%20al.%20A%20Comprehensive%20Analysis%20of%20Key%20Immune%20Checkpoint%20Receptors%20on%20Tumor-Infiltrating%20T%20Cells%20From%20Multiple%20Types%20of%20Cancer.%20Front%20Oncol.9,%201066%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Zhou, C. et al. Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. <em>J. Thorac. Oncol.</em><strong>18</strong>, 93–105 (2023).
</cite> [<a href="https://doi.org/10.1016/j.jtho.2022.09.217" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36184068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou,%20C.%20et%20al.%20Tislelizumab%20Versus%20Docetaxel%20in%20Patients%20With%20Previously%20Treated%20Advanced%20NSCLC%20(RATIONALE-303):%20A%20Phase%203,%20Open-Label,%20Randomized%20Controlled%20Trial.%20J.%20Thorac.%20Oncol.18,%2093%E2%80%93105%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Kim, T. W. et al. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. <em>JAMA Oncol.</em><strong>9</strong>, 1574–1582 (2023).
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2023.3867" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10540058/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37768658/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim,%20T.%20W.%20et%20al.%20Anti-TIGIT%20Antibody%20Tiragolumab%20Alone%20or%20With%20Atezolizumab%20in%20Patients%20With%20Advanced%20Solid%20Tumors:%20A%20Phase%201a/1b%20Nonrandomized%20Controlled%20Trial.%20JAMA%20Oncol.9,%201574%E2%80%931582%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Lamarca, A., Barriuso, J., McNamara, M. G. &amp; Valle, J. W. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. <em>J. Hepatol.</em><strong>73</strong>, 170–185 (2020).
</cite> [<a href="https://doi.org/10.1016/j.jhep.2020.03.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32171892/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lamarca,%20A.,%20Barriuso,%20J.,%20McNamara,%20M.%20G.%20&amp;%20Valle,%20J.%20W.%20Molecular%20targeted%20therapies:%20Ready%20for%20%E2%80%9Cprime%20time%E2%80%9D%20in%20biliary%20tract%20cancer.%20J.%20Hepatol.73,%20170%E2%80%93185%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12368246/bin/41392_2025_2356_MOESM1_ESM.doc" data-ga-action="click_feat_suppl" class="usa-link">Statistical Analysis Plan</a><sup> (169KB, doc) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12368246/bin/41392_2025_2356_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">CONSORT_2025_editable_checklist</a><sup> (34.1KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12368246/bin/41392_2025_2356_MOESM3_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Sigtrans_Supplementary_Materials</a><sup> (4.2MB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12368246/bin/41392_2025_2356_MOESM4_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Study protocol</a><sup> (551.8KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The datasets supporting the findings of the current study are included in the manuscript and its Supplemental Materials. The datasets are available from the corresponding author upon reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Signal Transduction and Targeted Therapy are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41392-025-02356-y"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41392_2025_Article_2356.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.7 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12368246/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12368246/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12368246%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368246/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12368246/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12368246/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40835595/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12368246/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40835595/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12368246/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12368246/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="v0AMh8WM7aQdXXwu6kpdN42k4PliObRGtU9uHayC6Oj1fOlcwGYmRX69zJPk53cX">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
